232 related articles for article (PubMed ID: 28849022)
1. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
2. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
3. Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.
Rao SR; Alham NK; Upton E; McIntyre S; Bryant RJ; Cerundolo L; Bowes E; Jones S; Browne M; Mills I; Lamb A; Tomlinson I; Wedge D; Browning L; Sirinukunwattana K; Palles C; Hamdy FC; Rittscher J; Verrill C
J Mol Diagn; 2020 May; 22(5):652-669. PubMed ID: 32229180
[TBL] [Abstract][Full Text] [Related]
4. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
Ma C; Wang X; Dai JY; Turman C; Kraft P; Stopsack KH; Loda M; Pettersson A; Mucci LA; Stanford JL; Penney KL
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1436-1443. PubMed ID: 37555839
[TBL] [Abstract][Full Text] [Related]
5. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
6.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
7. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
8. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
10. Induced chromosomal proximity and gene fusions in prostate cancer.
Mani RS; Tomlins SA; Callahan K; Ghosh A; Nyati MK; Varambally S; Palanisamy N; Chinnaiyan AM
Science; 2009 Nov; 326(5957):1230. PubMed ID: 19933109
[TBL] [Abstract][Full Text] [Related]
11. ERG oncogene modulates prostaglandin signaling in prostate cancer cells.
Mohamed AA; Tan SH; Sun C; Shaheduzzaman S; Hu Y; Petrovics G; Chen Y; Sesterhenn IA; Li H; Sreenath T; McLeod DG; Dobi A; Srivastava S
Cancer Biol Ther; 2011 Feb; 11(4):410-7. PubMed ID: 21178489
[TBL] [Abstract][Full Text] [Related]
12. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
Ahearn TU; Peisch S; Pettersson A; Ebot EM; Zhou CK; Graff RE; Sinnott JA; Fazli L; Judson GL; Bismar TA; Rider JR; Gerke T; Chan JM; Fiorentino M; Flavin R; Sesso HD; Finn S; Giovannucci EL; Gleave M; Loda M; Li Z; Pollak M; Mucci LA;
Carcinogenesis; 2018 Dec; 39(12):1431-1437. PubMed ID: 30165429
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ERG responsive proteome in prostate cancer.
Tan SH; Furusato B; Fang X; He F; Mohamed AA; Griner NB; Sood K; Saxena S; Katta S; Young D; Chen Y; Sreenath T; Petrovics G; Dobi A; McLeod DG; Sesterhenn IA; Saxena S; Srivastava S
Prostate; 2014 Jan; 74(1):70-89. PubMed ID: 24115221
[TBL] [Abstract][Full Text] [Related]
14. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
15. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
16. Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images.
Omar M; Xu Z; Rand SB; Alexanderani MK; Salles DC; Valencia I; Schaeffer EM; Robinson BD; Lotan TL; Loda M; Marchionni L
Mol Cancer Res; 2024 Apr; 22(4):347-359. PubMed ID: 38284821
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract][Full Text] [Related]
18. RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.
Gu JL; Chukhman M; Lu Y; Liu C; Liu SY; Lu H
Biomed Res Int; 2017; 2017():9829175. PubMed ID: 29181411
[TBL] [Abstract][Full Text] [Related]
19. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Wang X; Qiao Y; Asangani IA; Ateeq B; Poliakov A; Cieślik M; Pitchiaya S; Chakravarthi BVSK; Cao X; Jing X; Wang CX; Apel IJ; Wang R; Tien JC; Juckette KM; Yan W; Jiang H; Wang S; Varambally S; Chinnaiyan AM
Cancer Cell; 2017 Apr; 31(4):532-548.e7. PubMed ID: 28344039
[TBL] [Abstract][Full Text] [Related]
20. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
Wilson S; Greer B; Hooper J; Zijlstra A; Walker B; Quigley J; Hawthorne S
Biochem J; 2005 Jun; 388(Pt 3):967-72. PubMed ID: 15537383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
